As a cancer epidemiogist with a background in basic science, the primary objective of my research program is to improve our overall understanding of urologic malignancies (e.g. renal, prostate and bladder cancers). More importantly, my ultimate goal is to help translate this new understanding into better treatment for patients and better cancer prevention efforts for the population at large.
Related to this, my primary area of interest centers on identification and validation of biomarkers of renal cell carcinoma (RCC) aggressiveness. That is, we are exploring tumor=-based, germline and immunologic biomarkers associated iwth RCC aggressiveness and survival that not only could be used to enhance patient management and stratification for clinical trials but also could lead to new avenues for therapeutics.
My other areas of interest in cancer include risk factors for RCC, prostate cancer outcomes and smoking and bladder cancer etiology.